Skip to main content
SpringerLink
Log in

Zystoides Makulaödem bei Uveitis

Cystoid macular edema in uveitis

  • Leitthema
  • Published:
Der Ophthalmologe Aims and scope Submit manuscript

Zusammenfassung

Zystoide Makulaödeme sind die häufigste Ursache einer Visusverschlechterung bei Uveitis. Als Folge der Entzündung kommt es zu Störungen der Blut-Retina-Schranke, einer Akkumulation von Protein in der Netzhaut und zum Ödem. Zur Therapie muss eine konsequente antientzündliche Behandlung begonnen werden. Zur Stabilisierung der Blut-Retina-Schranke werden Steroide und nichtsteroidale Antiphlogistika eingesetzt. Der Abtransport von extrazellulärer Flüssigkeit kann durch systemische Karboanhydrasehemmer verbessert werden. Trotz aggressiver Therapie kann langfristig ein ungünstiger Verlauf nicht immer vermieden werden, daher sind eine frühzeitige Diagnostik und ein Therapiebeginn auch bei noch sehr gutem Sehvermögen erforderlich.

Abstract

Cystoid macular edema (CME) is the most frequent cause of visual deterioration in uveitis patients. Intraocular inflammation disturbs the blood-retina barrier and leads to retinal edema. The basis of successful treatment is the anti-inflammatory and immunosuppressive therapy of uveitis. Restoration of the blood-retina barrier is mediated by corticosteroids and nonsteroidal anti-inflammatory agents. Resorption of extracellular fluid is improved by systemic carboanhydrase inhibitors. Despite aggressive therapy loss of visual acuity is frequent. Therefore, early diagnosis of CME and initiation of treatment, even if visual acuity is not yet impeded, is mandatory.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1
Abb. 2
Abb. 3

Literatur

  1. Aiello LP, Brucker AJ, Chang S et al. (2004) Evolving guidelines for intravitreous injections. Retina 24:3–19

    Google Scholar 

  2. Antcliff RJ, Spalton DJ, Stanford MR, Graham EM, Ffytche TJ, Marshall J (2001) Intravitreal triamcinolone for uveitic cystoid macular edema: an optical coherence tomography study. Ophthalmology 108:765–772

    Google Scholar 

  3. Antcliff RJ, Stanford MR, Chauhan DS et al. (2000) Comparison between optical coherence tomography and fundus fluorescein angiography for the detection of cystoid macular edema in patients with uveitis. Ophthalmology 107:593–599

    Article  CAS  PubMed  Google Scholar 

  4. Antonetti DA, Wolpert EB, DeMaio L, Harhaj NS, Scaduto RC (2002) Hydrocortisone decreases retinal endothelial cell water and solute flux coincident with increased content and decreased phosphorylation of occludin. J Neurochem 80:667–677

    Google Scholar 

  5. Bailey TA, Kanuga N, Romero IA, Greenwood J, Luthert PJ, Cheetham ME (2004) Oxidative stress affects the junctional integrity of retinal pigment epithelial cells. Invest Ophthalmol Vis Sci 45:675–684

    Google Scholar 

  6. Becker MD, Heiligenhaus A, de Smet M, Davis JL (2005) Vitrectomy in uveitis. In: Pleyer U, Mondino B (eds) Uveitis and immunological disorders. Springer, Berlin Heidelberg New York Tokio, pp 273–284

  7. Bunt Milam AH, Saari JC, Klock IB, Garwin GG (1985) Zonulae adherentes pore size in the external limiting membrane of the rabbit retina. Invest Ophthalmol Vis Sci 26:1377–1380

    Google Scholar 

  8. Castro MR, Lutz D, Edelman JL (2004) Effect of COX inhibitors on VEGF-induced retinal vascular leakage and experimental corneal and choroidal neovascularization. Exp Eye Res 79:275–285

    Google Scholar 

  9. Durrani OM, Tehrani NN, Marr JE, Moradi P, Stavrou P, Murray PI (2004) Degree, duration, and causes of visual loss in uveitis. Br J Ophthalmol 88:1159–1162

    Article  Google Scholar 

  10. Freeman G (2001) Cystoid macular oedema in uveitis: an unsolved problem. Eye 15:12–17

    Google Scholar 

  11. Gillies MC (1999) Regulators of vascular permeability: potential sites for intervention in the treatment of macular edema. Doc Ophthalmol 97:251–260

    Google Scholar 

  12. Guex Crosier Y (1999) The pathogenesis and clinical presentation of macular edema in inflammatory diseases. Doc Ophthalmol 97:297–309

    Article  Google Scholar 

  13. Jaissle GB, Szurman P, Bartz Schmidt KU (2004) Nebenwirkungen und Komplikationen der intravitrealen Triamcinolonacetonid-Therapie. Ophthalmologe 101:121–128

    Google Scholar 

  14. Jonas JB, Kreissig I, Kamppeter B, Degenring RF (2004) Intravitreales Triamcinolonacetonid zur Behandlung intraokularer ödematoser und neovaskulärer Erkrankungen. Ophthalmologe 101:113–120

    Google Scholar 

  15. Karacorlu M, Mudun B, Ozdemir H, Karacorlu SA, Burumcek E (2004) Intravitreal triamcinolone acetonide for the treatment of cystoid macular edema secondary to Behcet disease. Am J Ophthalmol 138:289–291

    Google Scholar 

  16. Lashay AR, Rahimi A, Chams H et al. (2003) Evaluation of the effect of acetazolamide on cystoid macular oedema in patients with Behcet’s disease. Eye 17:762–766

    Google Scholar 

  17. Markomichelakis NN, Halkiadakis I, Pantelia E, Peponis V, Patelis A, Theodossiadis P, Theodossiadis G (2004) Patterns of macular edema in patients with uveitis: qualitative and quantitative assessment using optical coherence tomography. Ophthalmology 111:946–953

    Google Scholar 

  18. Martidis A, Duker JS, Puliafito CA (2001) Intravitreal triamcinolone for refractory cystoid macular edema secondary to birdshot retinochoroidopathy. Arch Ophthalmol 119:1380–1383

    Google Scholar 

  19. Miyake K, Ibaraki N (2002) Prostaglandins and cystoid macular edema. Surv Ophthalmol 47 [Suppl 1]:S203–218

    Google Scholar 

  20. Rojas B, Zafirakis P, Christen W, Markomichelakis NN, Foster CS (1999) Medical treatment of macular edema in patients with uveitis. Doc Ophthalmol 97:399–407

    Google Scholar 

  21. Rothova A (2002) Medical treatment of cystoid macular edema. Ocul Immunol Inflamm 10:239–246

    Google Scholar 

  22. Rothova A, Suttorp van Schulten MS, Frits Treffers W, Kijlstra A (1996) Causes and frequency of blindness in patients with intraocular inflammatory disease. Br J Ophthalmol 80:332–336; Issn: 0007–1161

  23. Tamesis RR, Rodriguez A, Christen WG, Akova YA, Messmer E, Foster CS (1996) Systemic drug toxicity trends in immunosuppressive therapy of immune and inflammatory ocular disease. Ophthalmology 103:768–775; Issn: 0161–6420

    Google Scholar 

  24. Thach AB, Dugel PU, Flindall RJ, Sipperley JO, Sneed SR (1997) A comparison of retrobulbar versus sub-Tenon’s corticosteroid therapy for cystoid macular edema refractory to topical medications. Ophthalmology 104:2003–2008

    Google Scholar 

  25. Thurau SR, Wildner G (2005) Immunomodulatory therapy in uveitis. In: Pleyer U, Mondino B (eds) Uveitis and immunological disorders. Springer, Berlin Heidelberg New York Tokio, pp 255–271

  26. Tretiach M, Madigan MC, Gillies MC (2004) Conditioned medium from mixed retinal pigmented epithelium and Muller cell cultures reduces in vitro permeability of retinal vascular endothelial cells. Br J Ophthalmol 88:957–961

    Google Scholar 

  27. Wiechens B, Reichelt JA, Urbat C, Nolle B (2003) Pars-plana-Vitrektomie bei zystoidem Makulaödem bei verschiedenen Formen der chronischen Uveitis. Ophthalmologe 100:33–43

    Google Scholar 

  28. Wolfensberger TJ (1999) The role of carbonic anhydrase inhibitors in the management of macular edema. Doc Ophthalmol 97:387–397

    Google Scholar 

  29. Young S, Larkin G, Branley M, Lightman S (2001) Safety and efficacy of intravitreal triamcinolone for cystoid macular oedema in uveitis. Clin Experiment Ophthalmol 29:2–6

    Google Scholar 

  30. Zierhut M, Thiel HJ, Schlote T (1999) Treatment of uveitic macular edema with acetazolamide. Doc Ophthalmol 97:409–413

    Google Scholar 

Download references

Danksagung

Ich danke Frau PD Dr. G. Wildner für die Hilfe bei der Erstellung des Manuskripts.

Interessenkonflikt:

Der korrespondierende Autor versichert, dass keine Verbindungen mit einer Firma, deren Produkt in dem Artikel genannt ist, oder einer Firma, die ein Konkurrenzprodukt vertreibt, bestehen.

Author information

Authors and Affiliations

  1. Augenklinik, Ludwig-Maximilians-Universität, München

    S. R. Thurau

  2. Augenklinik, Ludwig-Maximilians-Universität, Mathildenstraße 8, 80336, München

    S. R. Thurau

Authors
  1. S. R. Thurau
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to S. R. Thurau.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Thurau, S.R. Zystoides Makulaödem bei Uveitis. Ophthalmologe 102, 485–490 (2005). https://doi.org/10.1007/s00347-005-1183-9

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00347-005-1183-9

Schlüsselwörter

Keywords

Search

Navigation